CKPT - Checkpoint Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

86.78M

Cash

11.24M

Avg Qtr Burn

-10.01M

Short % of Float

14.64%

Insider Ownership

18.59%

Institutional Own.

15.68%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cosibelimab (CK-301) (Anti-PD-L1 Antibody) Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olafertinib (CK-101) (EGFR Inhibitor) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.